Pieris Pharmaceuticals Stock to Reverse Split on Tuesday, April 23rd (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)’s stock is set to reverse split before the market opens on Tuesday, April 23rd. The 1-80 reverse split was announced on Tuesday, April 23rd. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, April 23rd.

Pieris Pharmaceuticals Price Performance

PIRS traded down $0.01 on Friday, reaching $0.15. 1,919,826 shares of the company traded hands, compared to its average volume of 580,219. The stock’s 50 day moving average price is $0.17 and its 200-day moving average price is $0.20. Pieris Pharmaceuticals has a 52-week low of $0.14 and a 52-week high of $1.01. The company has a market cap of $14.34 million, a price-to-earnings ratio of -0.52 and a beta of 0.48.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.05) EPS for the quarter. Pieris Pharmaceuticals had a negative net margin of 57.33% and a negative return on equity of 90.17%. The company had revenue of $1.30 million for the quarter.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Pieris Pharmaceuticals in a research report on Saturday, April 13th. They set a “hold” rating on the stock.

Institutional Trading of Pieris Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Northern Trust Corp grew its position in Pieris Pharmaceuticals by 76.8% in the fourth quarter. Northern Trust Corp now owns 243,592 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 105,783 shares in the last quarter. Acadian Asset Management LLC grew its position in Pieris Pharmaceuticals by 64.8% in the third quarter. Acadian Asset Management LLC now owns 962,358 shares of the biotechnology company’s stock worth $286,000 after acquiring an additional 378,339 shares in the last quarter. CM Management LLC grew its position in Pieris Pharmaceuticals by 18.1% in the third quarter. CM Management LLC now owns 649,400 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 99,400 shares in the last quarter. JPMorgan Chase & Co. grew its position in Pieris Pharmaceuticals by 437.2% in the first quarter. JPMorgan Chase & Co. now owns 250,004 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 203,463 shares in the last quarter. Finally, State Street Corp grew its position in Pieris Pharmaceuticals by 6.9% in the first quarter. State Street Corp now owns 223,829 shares of the biotechnology company’s stock worth $218,000 after acquiring an additional 14,500 shares in the last quarter. 40.11% of the stock is owned by institutional investors.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.